- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.04. | Molecure biotech assumes about PLN 150 million in spending for 2024-2025 | 1 | PAP | ||
| 03.04. | Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025 | 98 | GlobeNewswire (Europe) | Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare... ► Artikel lesen | |
| 22.03. | Molecure: First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis | 27 | GlobeNewswire (Europe) | - OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase... ► Artikel lesen | |
| 19.12.23 | Molecure - Progressing the validation of mRNA platform | 340 | Edison Investment Research | Molecure has announced that it has generated the in vitro proof-of-concept (PoC) data for its mRNA platform, marking a step toward one of its long-term strategic objectives. Based on an in vitro study... ► Artikel lesen | |
| 06.11.23 | Molecure - Q323 report highlights clinical progress | 310 | Edison Investment Research | Molecure has released its Q323 report, providing an update on its clinical development activities, particularly around its oral, first-in-class inhibitor, OATD-01. Following the acceptance of the Investigational... ► Artikel lesen | |
| 31.10.23 | Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights | 254 | GlobeNewswire (Europe) | U.S. Food and Drug Administration (FDA) approval to conduct a Phase II clinical trial for novel chitinase inhibitor OATD-01 in pulmonary sarcoidosis with first patient expected to be dosed in fourth... ► Artikel lesen | |
| 04.10.23 | Molecure - Striving to maximise clinical potential | 362 | Edison Investment Research | Molecure has announced H123 results, including a recap of its operational activities. Management also outlined four strategic objectives for 2023-25, with the aim of creating a diversified portfolio... ► Artikel lesen | |
| 29.09.23 | Molecure Announces First Half 2023 Results - Significant Financial and Operating Momentum | 274 | GlobeNewswire (Europe) | Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential for breakthrough therapies for incurable diseasesCompleted... ► Artikel lesen | |
| 27.07.23 | Molecure - Ramp-up in preparation for busy clinical year | 365 | Edison Investment Research | In preparation for Molecure's forthcoming clinical and preclinical R&D activities, management has secured (secondary) financing with a gross value of around PLN50m (c $12m). The Phase II trial for OATD-01... ► Artikel lesen | |
| 24.07.23 | The U.S. Food and Drug Administration Gives the Green Light to Molecure's Flagship Program - Phase II Clinical Testing of OATD-01 is Ready for Launch | 35 | GlobeNewswire (Europe) | Press release The U.S. Food and Drug Administration Gives the Green Light to Molecure's Flagship Program - Phase II Clinical Testing of OATD-01 is Ready for Launch Molecure can proceed with clinical... ► Artikel lesen | |
| 21.07.23 | Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies | 260 | GlobeNewswire (Europe) | Press release Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable... ► Artikel lesen | |
| 26.06.23 | Molecure - OATD-01 gearing up for Phase II | 390 | Edison Investment Research | Molecure has filed an Investigational New Drug (IND) application with the US FDA for OATD-01. Clearance of the application will enable the company to initiate a global (US and EU), multi-centre, randomised... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,446 | -5,15 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
| IMMATICS | 9,240 | +1,26 % | Immatics Announces Full Year 2023 Financial Results and Corporate Update | Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up... ► Artikel lesen | |
| ALDEYRA | 3,772 | +2,84 % | Aldeyra Therapeutics, Inc. - 8-K, Current Report | ||
| MEDIFAST | 31,190 | -0,06 % | Medifast Announces Fourth Quarter and Full Year 2023 Financial Results | BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth... ► Artikel lesen | |
| PHARMING | 0,890 | 0,00 % | Pharming Group N.V.: Pharming Group to report first quarter 2024 financial results on May 8 | Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results... ► Artikel lesen | |
| COHERUS | 1,824 | +1,11 % | Coherus BioSciences, Inc.: Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| ARCA BIOPHARMA | 3,220 | -1,23 % | ARCA biopharma GAAP EPS of -$0.14 | ||
| BRAINSTORM CELL THERAPEUTICS | 0,520 | +5,16 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn | Bob Dagher, MD, Promoted to Chief Medical Officer
Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors
NEW YORK, April 16, 2024 /PRNewswire/ -- BrainStorm Cell... ► Artikel lesen | |
| INNOVIVA | 14,300 | +2,14 % | Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 | Single-dose, oral zoliflodacin achieved 90.9% microbiological cure rate, demonstrating statistical non-inferiority compared to current global standard of care Pivotal Phase 3 data to be... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 2,380 | -0,83 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update | LOS ANGELES, March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage... ► Artikel lesen | |
| DBV TECHNOLOGIES | 1,154 | +1,41 % | DBV Technologies S.A.: Combined General Meeting of May 16, 2024 | Châtillon, France, April 25, 2024
Combined General Meeting of May 16, 2024
Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting
DBV Technologies... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,640 | -0,23 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MATINAS BIOPHARMA | 0,176 | +3,66 % | Matinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update | Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded... ► Artikel lesen | |
| DECIPHERA PHARMACEUTICALS | 13,600 | -0,73 % | Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results | WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 19,200 | 0,00 % | Syndax Pharmaceuticals, Inc.: Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session | - Consistent safety and efficacy profiles across adult and pediatric populations -
- Majority of pediatric patients who achieved an overall response proceeded to transplant; patients receiving post-transplant... ► Artikel lesen |
MOLECURE SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,060 (-1,78 %) liegt der Kurs bei 3,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
